Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat
Breast Cancer Research2012Vol. 14(3), pp. R79–R79
Citations Over TimeTop 10% of 2012 papers
Chandra R. Tate, Lyndsay V. Rhodes, H. Chris Segar, Jennifer Driver, F. Nell Pounder, Matthew E. Burow, Bridgette M. Collins‐Burow
Abstract
This study revealed that panobinostat is overtly toxic to TNBC cells in vitro and decreases tumorigenesis in vivo. Additionally, treatment up-regulated anti-proliferative, tumor suppressor, and epithelial marker genes in MDA-MB-231 cells and initiated a partial reversal of the epithelial-to-mesenchymal transition. Our results demonstrate a potential therapeutic role of panobinostat in targeting aggressive triple-negative breast cancer cell types.
Related Papers
- → Supplementary Figure S3 from The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects(2023)
- → Supplementary Figure S4 from The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects(2023)
- → Supplementary Figure S4 from The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects(2023)
- → Supplementary Table S1 from The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects(2023)
- → Supplementary Table S2 from The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects(2023)